Ph 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study Announced
“We continue to be encouraged by evidence for therapeutic potential, in the form of multiple patients with durable clinical benefit from ’610,” said Jennifer Low, M.D., Ph.D., Head of Therapeutics Development, 23andMe. “Furthermore, the emergence of CD200 expression as a candidate biomarker has the potential to give us a powerful tool for patient selection. The progress we have made to date suggests that interrupting the CD200/CD200R1 pathway has great potential to reverse immune suppression in the tumor microenvironment and to help cancer patients who have progressed after multiple lines of treatment, including existing checkpoint inhibitors.”
Share:
More News
“Between 2017 and 2023, the socioeconomic burden of HER2-positive breast cancer in ten major economies was nearly $590 billion, projected to increase to nearly $1,000 billion by 2032,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At-home treatment may help alleviate the pressure
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
“Beyond the second-line monotherapy opportunity, we and our partners at Pfizer have removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan,” continued Dr. Houston. “This decision was made following
“The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.”
